Summary - A new market study, titled “Global Thrombocytopenia (Immune & Chemotherapy-induced) Market Size, Status and Forecast 2020-2026” has been featured on WiseGuy Reports.
The global immune thrombocytopenia (ITP) market is expected to reach 2.27 billion in 2023, growing at a CAGR of 5.82%, for the duration spanning 2019-2023. The factors such as, rising healthcare expenditures, growing female population, rising prevalence of arthritis, increasing incidences of hepatitis C and new cases of diagnosed cancer would drive the growth of the market. However, market growth would be challenged by the lethargic drug approval process, side effects associated with available thrombocytopenia drugs and the availability of alternative treatment options. A few notable trends include, novel drug development for thrombocytopenia, increasing number of awareness programs against thrombocytopenia, and increasing preferences for biosimilars.
The global thrombocytopenia market would witness considerable growth in coming years, due to the rising prevalence of thrombocytopenia and associated risk factors. The most common type of thrombocytopenia is ITP, which is highly prevalent in patients with rheumatoid arthritis. Whereas, CIT (Chemotherapy-Induced Thrombocytopenia) occurs in patients with cancer, due to the involvement of chemotherapy and radiation treatment. Thrombocytopenia in patients with CLD is growing rapidly with an increase in incidences of HCV infections among them.
ALSO READ: https://www.medgadget.com/2020/10/thrombocytopenia-market-2020-glob...

Scope of the report:
• The report provides a comprehensive analysis of the global thrombocytopenia (Immune and Chemotherapy-induced) market.
• The major regional market (the U.S.) has been analyzed.
• The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
• The competitive landscape of the market, along with the company profiles of leading players (Novartis AG, Merck and Co., CSL Limited, Amgen Pharmaceuticals, Horizon Therapeutics and Rigel Pharmaceuticals) are also presented in detail.
Key Target Audience:
• Thrombocytes Drugs Manufacturers
• Chemical Suppliers
• End Users (Hospital, Medical Centers, Clinical Institutes)
• Healthcare Consulting Firms
• Investment Banks
• Government Bodies & Regulating Authorities

FOR MORE DETAILS: https://www.wiseguyreports.com/reports/5266268-global-thrombocytope...

About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Contact Us:
NORAH TRENT
sales@WiseGuy Reports.com
Ph: +162-825-80070 (US)
Ph: +44 203 500 2763 (UK)